Blue Water Vaccines to Present at the JMP Securities Life Science Conference
June 06 2022 - 10:30AM
Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the
Company”), a biopharmaceutical company developing transformational
vaccines to address significant global health challenges, today
announced that Joseph Hernandez, Chairman and Chief Executive
Officer of BWV, will present at the JMP Securities Life Science
Conference. Mr. Hernandez will present a corporate overview and
update for BWV’s vaccine candidate pipeline.
Session details are as follows:
Date: |
Wednesday, June 15, 2022 |
Time: |
11:30am Eastern Daylight Time
(EDT) |
Title: |
Blue Water Vaccines Company
Presentation |
BWV
Participant: |
Joseph Hernandez, Chairman and
Chief Executive Officer |
“We are honored to share our company mission and progress with
such an esteemed group of investors and colleagues in the
biotechnology space,” said Hernandez. “We have had several exciting
updates throughout the year, including corporate updates to
financing, agreements with collaborators, as well as data releases
for our vaccine candidates and look forward to sharing these with
all in attendance.”
BWV’s management will be available during the conference for
one-on-one meetings. Interested parties may request a one-on-one
meeting at investors@bluewatervaccines.com or contact BWV
at (513) 620-4101.
About Blue Water Vaccines
Blue Water Vaccines Inc. is a biopharmaceutical company focused
on developing transformational vaccines to address significant
health challenges globally. Headquartered in Cincinnati, OH, the
company holds the rights to proprietary technology developed at the
University of Oxford, Cincinnati Children's Hospital Medical Center
(CCHMC), and St. Jude Children's Hospital. The company is
developing a universal flu vaccine that will provide protection
from all virulent strains in addition to licensing a novel
norovirus (NoV) S&P nanoparticle versatile virus-like particle
(VLP) vaccine platform from CCHMC to develop vaccines for multiple
infectious diseases, including norovirus/rotavirus and malaria,
among others. Additionally, Blue Water Vaccines is developing a
Streptococcus pneumoniae (pneumococcus) vaccine candidate, designed
to specifically prevent the highly infectious middle ear
infections, known as Acute Otitis Media (AOM), in children. For
more information, visit www.bluewatervaccines.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements may be identified by the use of
forward-looking words such as “anticipate,” “believe,” “forecast,”
“estimate,” “expect,” and “intend,” among others. These
forward-looking statements are based on BWV’s current expectations
and actual results could differ materially. There are a number of
factors that could cause actual events to differ materially from
those indicated by such forward-looking statements. These factors
include, but are not limited to, risks related to the development
of BWV’s vaccine candidates; the failure to obtain FDA clearances
or approvals and noncompliance with FDA regulations; delays and
uncertainties caused by the global COVID-19 pandemic; risks related
to the timing and progress of clinical development of our product
candidates; our need for additional financing; uncertainties of
patent protection and litigation; uncertainties of government or
third party payor reimbursement; limited research and development
efforts and dependence upon third parties; and substantial
competition. As with any vaccine under development, there are
significant risks in the development, regulatory approval and
commercialization of new products. BWV does not undertake an
obligation to update or revise any forward-looking statement.
Investors should read the risk factors set forth in BWV’s Annual
Report on Form 10-K for the fiscal year ended December 31, 2021,
filed with the Securities and Exchange Commission (the “SEC”) on
March 31, 2022, and periodic reports filed with the SEC on or after
the date thereof. All of BWV’s forward-looking statements are
expressly qualified by all such risk factors and other cautionary
statements. The information set forth herein speaks only as of the
date thereof.
Investor Contact Information:Investor
RelationsEmail: investors@bluewatervaccines.com
Media Contact Information:Media
Relations513-620-4101Email: media@bluewatervaccines.com
Blue Water Biotech (NASDAQ:BWV)
Historical Stock Chart
From Jun 2024 to Jul 2024
Blue Water Biotech (NASDAQ:BWV)
Historical Stock Chart
From Jul 2023 to Jul 2024